Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a summary of its 2021 antiviral drug program so far this year, noting that all objectives in evaluating its proprietary DehydraTECH(TM) drug-delivery platform have been achieved. In addition, the company also discussed next steps. In short, the company stated thatit has successfully tested and released summary results on five different compounds from three antiviral drug classes, with results gathered that indicate up to a threefold increase in oral drug delivery into the bloodstream upon animal testing when processed with DehydraTECH. According to the announcement, the company has been able to determine whether DehydraTECH processing of compounds from leading classes of antiviral drugs for SARS-CoV-2/COVID-19, HIV/AIDS and other infectious diseases had the ability to exhibit evidence of superior oral absorption relative to controls. In addition, testing has shown whether DehydraTECH processing of those compounds could preserve expected viral inhibitory performance upon efficacy testing in infected mammalian cells. In addition, the company noted that DehydraTECH neither alters nor degrades drug molecules chemically, resulting in the creation of new molecular entities. Looking forward, the company’s drug-testing program will likely include larger in vivo efficacy evaluations in animals infected with SARS-CoV-2, HIV or other infectious viruses. The announcement noted that Lexaria is focused on a comprehensive, multipronged program designed to gather and evaluate proof-of-concept safety, efficacy and formulation/scalability feasibility data for potential pharmaceutical industry partners to evaluate for expanded, collaborative product development.
To view the full press release, visit https://cnw.fm/1kd1y
About Lexaria Bioscience Corp.
Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaScience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
CannabisNewsWire 